Brief: Evogene Announces Successful Completion Of Phase 1 Clinical Study Of Bmc128, A Rationally Designed Live Bacterial Product, In Combination With Nivolumab By Its Subsidiary Biomica
02/06/2026 12:15
BRIEF-Evogene Announces Successful Completion Of Phase 1 Clinical Study Of Bmc128, A Rationally Designed Live Bacterial Product, In Combination With Nivolumab By Its Subsidiary Biomica June 2 (Reuters) - Evogene Ltd EVGN.TA:
EVOGENE ANNOUNCES SUCCESSFUL COMPLETION OF PHASE 1 CLINICAL STUDY OF BMC128, A RATIONALLY DESIGNED LIVE BACTERIAL PRODUCT, IN COMBINATION WITH NIVOLUMAB BY ITS SUBSIDIARY BIOMICA
EVOGENE - STUDY MET PRIMARY ENDPOINT WITH FAVORABLE SAFETY, NO DOSE-LIMITING TOXICITIES
EVOGENE LTD: STUDY RESULTS DEMONSTRATED FAVORABLE SAFETY PROFILE AND PRELIMINARY SIGNALS OF CLINICAL ACTIVITY
Source text: ID:nPnbyG1xpa
Further company coverage: EVGN.TA
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Evogene
See all newsBrief: Evogene Itay Maroz And Shahar Zadok To Replace Dan Falk And Adrian Percy As Directors
Brief: Evogene And Pure Capital Group Reach Cooperation Agreement To Resolve Differences And Reconstitute Board Of Directors
Brief: Evogene Reports Second Quarter And First Half 2026 Financial Results
Freight booking platform Freightos jumps after quarterly revenue beat
Brief: Evogene Announces Successful Completion Of Phase 1 Clinical Study Of Bmc128, A Rationally Designed Live Bacterial Product, In Combination With Nivolumab By Its Subsidiary Biomica